No-carrier-added iodine-131-FIBG: evaluation of an MIBG analog.

Journal Article (Academic article)

The purpose of this study was to evaluate the properties of 4-fluoro-3-[131I]iodobenzylguanidine ([131I]FIBG), a potential neuroendocrine tumor and myocardial imaging radiopharmaceutical. METHODS: The binding of [131I]FIBG and [125I]MIBG was compared in vitro using the SK-N-SH human neuroblastoma cell line. The role of the active uptake-1 mechanism was investigated by determining the effect on cell binding of desipramine (DMI), ouabain, norepinephrine (NE), unlabeled MIBG and FIBG and by incubation at 4 degrees C. Finally, the tissue distributions of [131I]FIBG and [125I]MIBG were compared in normal mice. RESULTS: The specific binding of [131I]FIBG remained fairly constant (45%-60%) over a 2-3-log activity range and consistently was 11%-14% higher (p

Duke Authors

Cited Authors

  • Vaidyanathan, G; Zhao, XG; Strickland, DK; Zalutsky, MR

Published Date

  • February 1997

Published In

Volume / Issue

  • 38 / 2

Start / End Page

  • 330 - 334

PubMed ID

  • 9025764

International Standard Serial Number (ISSN)

  • 0161-5505

Conference Location

  • united states